[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633472":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Post Covid Syndrome",null,"PET imaging through the C11 ER176 tracer",[13],"Drug: C11 ER176 Tracer",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","C11 ER176 Tracer","C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation",[9],[21],{"name":22,"affiliation":5,"role":23},"Ryan T. Hurt, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Katie Cruz","CONTACT","507-284-5404","Cruz.Katie@mayo.edu",[31],{"facility":5,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Rochester","Minnesota","55905","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-92.4699,44.02163,{"lat":41,"lon":40},{"type":23,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ryan T. Hurt, M.D., Ph.D.","Principal Investigator","100633472","c11-er176-pet-in-evaluating-neuroinflammation-in-patients-with-post-covid-syndrome-100633472",false,"NCT07527130","C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome","Inclusion Criteria:\n\n* Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine \\& Health Section or approval by MAGPIES research group.\n* Be able to participate fully in all aspects of the study.\n* Have understood and signed study informed consent.\n\nExclusion Criteria:\n\n* Lacking the capacity to consent.\n* Prisoners and institutionalized individuals.\n* Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.\n\n  o Acceptable forms include:\n  * Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants\n  * Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)\n  * Intrauterine device (IUD)\n  * Total hysterectomy or tubal ligation\n  * Abstinence (no sex).\n* Those patients that have implants that would prevent them from having a PET Scan.\n* Patients that have claustrophobia.\n* Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.","ALL","18 Years",{"count":55,"type":56},10,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.",[60],"COVID-19","NOT_YET_RECRUITING","2026-04-21",{"date":64,"type":65},"2026-04-24","ACTUAL",{"date":67,"type":56},"2026-05",{"date":69,"type":56},"2027-12",{"name":5,"class":6},1]